Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.
2.

Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.

Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, Mandel RJ, Björklund A.

J Neurosci. 2002 Apr 1;22(7):2780-91.

3.

Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects.

Khodr CE, Becerra A, Han Y, Bohn MC.

Brain Res. 2014 Mar 6;1550:47-60. doi: 10.1016/j.brainres.2014.01.010. Epub 2014 Jan 21.

4.

Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein.

Koprich JB, Johnston TH, Huot P, Reyes MG, Espinosa M, Brotchie JM.

PLoS One. 2011 Mar 7;6(3):e17698. doi: 10.1371/journal.pone.0017698.

5.

Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.

Decressac M, Mattsson B, Lundblad M, Weikop P, Björklund A.

Neurobiol Dis. 2012 Mar;45(3):939-53. doi: 10.1016/j.nbd.2011.12.013. Epub 2011 Dec 11.

PMID:
22182688
6.

Novel AAV-based rat model of forebrain synucleinopathy shows extensive pathologies and progressive loss of cholinergic interneurons.

Aldrin-Kirk P, Davidsson M, Holmqvist S, Li JY, Björklund T.

PLoS One. 2014 Jul 7;9(7):e100869. doi: 10.1371/journal.pone.0100869. eCollection 2014.

7.

Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons.

Lundblad M, Decressac M, Mattsson B, Björklund A.

Proc Natl Acad Sci U S A. 2012 Feb 28;109(9):3213-9. doi: 10.1073/pnas.1200575109. Epub 2012 Feb 6.

8.

Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.

Connor B, Kozlowski DA, Unnerstall JR, Elsworth JD, Tillerson JL, Schallert T, Bohn MC.

Exp Neurol. 2001 May;169(1):83-95.

PMID:
11312561
9.

rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.

Oliveras-Salvá M, Van der Perren A, Casadei N, Stroobants S, Nuber S, D'Hooge R, Van den Haute C, Baekelandt V.

Mol Neurodegener. 2013 Nov 25;8:44. doi: 10.1186/1750-1326-8-44.

10.

Heat shock protein 70 reduces α-synuclein-induced predegenerative neuronal dystrophy in the α-synuclein viral gene transfer rat model of Parkinson's disease.

Moloney TC, Hyland R, O'Toole D, Paucard A, Kirik D, O'Doherty A, Gorman AM, Dowd E.

CNS Neurosci Ther. 2014 Jan;20(1):50-8. doi: 10.1111/cns.12200. Epub 2013 Nov 27.

PMID:
24279716
11.

Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease.

Decressac M, Mattsson B, Björklund A.

Exp Neurol. 2012 May;235(1):306-15. doi: 10.1016/j.expneurol.2012.02.012. Epub 2012 Feb 25.

PMID:
22394547
12.

Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease.

Sato H, Arawaka S, Hara S, Fukushima S, Koga K, Koyama S, Kato T.

J Neurosci. 2011 Nov 16;31(46):16884-94. doi: 10.1523/JNEUROSCI.3967-11.2011.

13.

Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity.

Gaugler MN, Genc O, Bobela W, Mohanna S, Ardah MT, El-Agnaf OM, Cantoni M, Bensadoun JC, Schneggenburger R, Knott GW, Aebischer P, Schneider BL.

Acta Neuropathol. 2012 May;123(5):653-69. doi: 10.1007/s00401-012-0963-y. Epub 2012 Feb 24.

PMID:
22361813
15.

Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.

Maingay M, Romero-Ramos M, Carta M, Kirik D.

Neurobiol Dis. 2006 Sep;23(3):522-32. Epub 2006 Jun 30.

PMID:
16806952
16.

Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra.

St Martin JL, Klucken J, Outeiro TF, Nguyen P, Keller-McGandy C, Cantuti-Castelvetri I, Grammatopoulos TN, Standaert DG, Hyman BT, McLean PJ.

J Neurochem. 2007 Mar;100(6):1449-57. Epub 2007 Jan 4.

17.

Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function.

Oaks AW, Frankfurt M, Finkelstein DI, Sidhu A.

PLoS One. 2013;8(4):e60378. doi: 10.1371/journal.pone.0060378. Epub 2013 Apr 1.

18.

Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression.

Chung CY, Koprich JB, Hallett PJ, Isacson O.

Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22474-9. doi: 10.1073/pnas.0912193106. Epub 2009 Dec 10.

19.

Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system.

Gombash SE, Manfredsson FP, Kemp CJ, Kuhn NC, Fleming SM, Egan AE, Grant LM, Ciucci MR, MacKeigan JP, Sortwell CE.

PLoS One. 2013 Nov 27;8(11):e81426. doi: 10.1371/journal.pone.0081426. eCollection 2013.

20.

Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease.

Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, Björklund A.

Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2884-9. Epub 2003 Feb 24.

Items per page

Supplemental Content

Write to the Help Desk